Psychopharmacology Enduring Activity (Nebraska)

This psychiatry conference examines the latest research and treatment advances across dozens of mental health conditions. It offers in-depth information that is important for all mental health and primary care settings. Topics include ADHD, anxiety, bipolar disorder, depression, OCD, psychosis, PTSD, substance use disorders, and much more.

In every session, our faculty share any data from new clinical trials. They match it up against prior data and discuss what the changes mean. They also examine standards of care and share innovative ways to make care better. The agenda touches on many complex topics in mental health. Managing side effects, drug interactions, natural medications, combining pharmacologic and psychosocial treatments, and much more.

Most important of all, our faculty focus on how to translate all these insights into your daily practice. This empowers you to optimize your care for patients with psychiatric conditions. That makes our event ideal for professionals in psychiatry, primary care, psychology, and nursing.

Target Audience

This program is intended for psychiatrists, psychologists, general and family practice physicians, psychiatric nurses, physician assistants, nurse practitioners, and social workers

Learning Objectives

By the end of this program, participants will be able to:

  1. identify rational, evidence-based pharmacologic and non-pharmacologic therapies for patients with unipolar, bipolar, treatment-resistant, and post-partum depression.
  2. Compare the neurobiology and evidence-based treatment approaches to addiction, anxiety, schizophrenia, and mood disorders.
  3. Review the course and treatment of psychiatric disorders during pregnancy and menopause.
  4. Analyze drug interactions and the pharmacotherapy of adult ADHD and geriatric disorders.
  5. Apply newer strategies in treatment of chemical abuse/dependence
  6. Analyze evidence-based treatment for psychiatric illness
  7. Assess the most recent state of the art treatment alternatives
  8. Assess new therapies and what is on the horizon
  9. Analyze the use of CBT based techniques
Course summary
Available credit: 
  • 23.00 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.

    McLean Hospital designates this Enduring activity for a maximum of 23.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

  • 23.00 Nursing Contact Hours

    Massachusetts General Laws, Chapter 13, sections 13, 14, 14A, 15 and 15D and Chapter 112, sections 74 through 81C authorize the Board of Registration in Nursing to regulate nursing practice and education.

    This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for 23.00 contact hours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet the requirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation.

  • 21.50 Social Workers

    The Collaborative of NASW, Boston College, and Simmons College Schools of Social Work authorizes social work continuing education credits for courses, workshops, and educational programs that meet the criteria outlined in 258 CMR of the Massachusetts Board of Registration of Social Workers

    This program has been approved for 21.50 Social Work Continuing Education hours for relicensure, in accordance with 258 CMR. Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D91727

  • 23.00 Participation

    This course allows other providers to claim a Participation Certificate upon successful completion of this course.

    Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1 Credit™ associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMA PRA Category 1 Credit™ may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.

  • 23.00 Psychologists CE Credit

    The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content.

    This offering meets the criteria for 23.00 Continuing Education (CE) credits per presentation for psychologists.

Registration opens: 
09/07/2023
Course closes: 
12/31/2024
Rating: 
0

Psychopharmacology Enduring Activity

 

DAY 1

MODULE TOPIC – MOOD DISORDERS

8:10 – 8:55AM           Bipolar Depression

Andrew A. Nierenberg, MD

8:55 – 9:40AM           Bipolar Long-Term Management

Roy H. Perlis, MD, MSc

9:55 – 10:40AM         Treatment Resistant Depression

Maurizio Fava, MD

10:40 – 11:20 AM      Panel Discussion

Moderator: Michael E. Henry, MD

Panelists: Andrew A. Nierenberg, MD, Roy H. Perlis, MD, MSc, Maurizio Fava, MD

 

MODULE TOPIC – ANXIETY/PTSD

12:20 – 1:05PM          PTSD

Eric Bui, MD, PhD

1:05 – 1:50PM            Anxiety Disorders and Treatments

                                    Eric Bui, MD, PhD

1:50 – 2:30PM            Panel Discussion

Moderator: Lee Cohen, MD

Panelists: Eric Bui, MD, PhD, Amanda Baker, PhD

 

MODULE TOPIC – WOMEN’S HEALTH

2:45 – 3:30PM            Course and Treatment of Mood and Anxiety Disorders During Pregnancy

Lee S. Cohen, MD

3:30 – 4:15PM            Postpartum Mood Disorders

Marlene P. Freeman, MD

4:15 – 4:55PM            Panel Discussion

Moderator: Lee S. Cohen, MD

Panelist:  Marlene P. Freeman, MD

 

DAY 2

MODULE TOPIC – PSYCHOSIS

8:05 – 8:50AM           First-Episode Psychosis and Schizophrenia

Oliver Freudenreich, MD, FACLP

8:50 – 9:35AM           Management of Side-Effects of Antipsychotics

Oliver Freudenreich, MD, FACLP

 

MODULE TOPIC – KETAMINE & ESKETAMINE

9:50 – 10:35AM         Ketamine and Esketamine: From Research to Clinical Practice

Cristina Cusin, MD

10:35 – 11:15AM       Panel Discussion

Moderator: David Mischoulon, MD

Panelists: Cristina Cusin, MD, Oliver Freudenreich, MD, FACLP

 

MODULE TOPIC – NEW THERAPIES: WHAT IS ON THE HORIZON?

12:15 – 1:00PM          Psychedelics

Franklin King, MD

1:00 – 1:45PM            New Treatments for Schizophrenia

Oliver Freudenreich, MD, FACLP

2:00 – 2:45PM            New Treatments for Mood Disorders

Michael E. Henry, MD & Joan Camprodon, MD, MPH, PhD

2:45 – 3:30PM            What is New in Addiction?

John F. Kelly, PhD

3:30 – 4:10PM            Panel Discussion

Moderator: John F. Kelly, PhD

Panelists: Michael E. Henry, MD, Joan Camprodon, MD, MPH, PhD; Franklin King, MD, Oliver Freudenreich, MD, FACLP

 

DAY 3

MODULE TOPIC – ADDICTION

8:05 – 8:50AM           Alcohol and Opioids

Vinod Rao, MD, PhD

8:50 – 9:35AM           Tobacco and Cocaine

Anne Eden Evins, MD

9:35 – 10:15AM         Panel Discussion

Moderator:  Anne Eden Evins, MD

Panelists: Vinod Rao, MD, PhD

 

MODULE TOPIC – OCD

10:30 – 11:15AM       OCD

Lisa M. Zakhary, MD, PhD

11:15 – 12:00PM        Obsessive-Compulsive Related Disorders  

Lisa M. Zakhary, MD, PhD

12:00 – 12:45PM        Cognitive Behavioral Therapy

Sabine Wilhelm, PhD

12:45 – 1:25PM          Panel Discussion

Moderator: Lisa M. Zakhary, MD, PhD

Panelists: Lisa M. Zakhary, MD, PhD, Sabine Wilhelm, PhD 

 

MODULE TOPIC – ACROSS THE LIFESPAN

2:25 – 3:10PM            Pediatric Bipolar Disorder and Mood Disorders

Janet Wozniak, MD

3:10 – 4:05PM            ADHD

Timothy Wilens, MD

4:05 – 4:50PM            Drug Interactions

Jonathan E. Alpert, MD, PhD

4:50 – 5:30PM            Panel Discussion

Moderator: Timothy Wilens, MD

Panelists: Jonathan E. Alpert, MD, Janet Wozniak, MD

PSYCHOPHARMACOLOGY ENDURING FACULTY LIST

Maurizio Fava, MD
Jerrold Rosenbaum, MD
Andrew A. Nierenberg, MD
Roy H. Perlis, MD, MSc
Eric Bui, MD, PhD
Lee Cohen, MD
Amanda Baker, MD
Marlene P. Freeman, MD
David Mischoulon, MD, PhD
David Rubin, MD
Oliver Freudenreich, MD, FACLP
Cristina Cusin, MD
Franklin King, MD
Michael E. Henry, MD
Joan Camprodon, MD, PhD
John F. Kelly, PhD
Vinod Rao, MD, PhD
Anne Eden Evins, MD
Lisa M. Zakhary, MD, PhD
Sabine Wilhelm, PhD
Janet Wozniak, MD
Michael A. Jenike, MD
Timothy E. Wilens, MD
Jonathan E. Alpert, MD, PhD

Available Credit

  • 23.00 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.

    McLean Hospital designates this Enduring activity for a maximum of 23.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

  • 23.00 Nursing Contact Hours

    Massachusetts General Laws, Chapter 13, sections 13, 14, 14A, 15 and 15D and Chapter 112, sections 74 through 81C authorize the Board of Registration in Nursing to regulate nursing practice and education.

    This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for 23.00 contact hours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet the requirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation.

  • 21.50 Social Workers

    The Collaborative of NASW, Boston College, and Simmons College Schools of Social Work authorizes social work continuing education credits for courses, workshops, and educational programs that meet the criteria outlined in 258 CMR of the Massachusetts Board of Registration of Social Workers

    This program has been approved for 21.50 Social Work Continuing Education hours for relicensure, in accordance with 258 CMR. Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D91727

  • 23.00 Participation

    This course allows other providers to claim a Participation Certificate upon successful completion of this course.

    Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1 Credit™ associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMA PRA Category 1 Credit™ may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.

  • 23.00 Psychologists CE Credit

    The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content.

    This offering meets the criteria for 23.00 Continuing Education (CE) credits per presentation for psychologists.

Please login or register to take this course.

Please enter access code "NEBRASKAONDEMAND" in order to proceed. 

 

Financial Relationships

The following planners, speakers, content reviewers, and others in control of educational content have reported financial relationships with ineligible companies over the past 24 months: 

Jonathan E. Alpert, MD, PhD
Editorial Fee: Belvoir Publishing, Cambridge University Press

Eric Bui, MD, PhD
Royalties: Springer, Wolters Kluwer
Consultant: Cerevel Therapeutics, LLC, NIH, DOD, PCORI

Joan Camprodon, MD, PhD, MPH 
SAB/Consultant: Hyka, Feelmore Labs, Mifu Technology

Lee S. Cohen, PhD
Consultant; Sponsor of National Pregnancy Registry for Psychiatric Medications: Alkermes Biopharmaceuticals; Sunovion Pharmaceuticals, Janssen Pharmaceuticals, Otsuka Pharmaceuticals, Teva Pharmaceutics, Sage Pharmaceuticals, Supernus Pharmaceuticals, Auromedics Pharma LLA, Aurobindo Pharma,
Other Research Support: Brain & Behavior Research Foundation; National Institute on Aging; National Institutes of Health; SAGE Therapeutics Advisory/Consulting: JDS Therapeutics LLC; As an employee of MGH, Dr. Cohen works with the MGH CTNI, which has had research funding from multiple pharmaceutical companies, including Alkermes Biopharmaceuticals and Praxis Precision Medicines, Inc., and the NIMH

Cristina Cusin, MD
Consultant: Perception Neuroscience, Compass Therapeutics, Clexio, Janssen

Eden Evins, MD, MPH
Consultant on NIDA grant: Charles River Analytics
Founder: HighLightI

Maurizio Fava, MD
Research Support: Abbott Laboratories; Acadia Pharmaceuticals; Alkermes, Inc.; American Cyanamid;Aspect Medical Systems; AstraZeneca; Avanir Pharmaceuticals; AXSOME Therapeutics; Biohaven; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon; Cerecor; Clarus Funds; Clexio Biosciences; Clintara, LLC; Covance; Covidien; Eli Lilly and Company;EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; FORUM Pharmaceuticals; Ganeden Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; Indivior; i3 Innovus/Ingenix; Janssen R&D, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck Inc.; Marinus Pharmaceuticals; MedAvante; Methylation Sciences Inc; National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM);National Coordinating Center for Integrated Medicine (NiiCM); National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Neuralstem, Inc.; NeuroRx; Novartis AG; Organon Pharmaceuticals; Otsuka Pharmaceutical Development, Inc.; PamLab, LLC.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates., Inc.; Pharmavite® LLC; PharmoRx Therapeutics; Photothera; Reckitt Benckiser; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shenox Pharmaceuticals, LLC; Shire; Solvay Pharmaceuticals, Inc.; Stanley Medical Research Institute (SMRI); Synthelabo; Taisho Pharmaceuticals; Takeda Pharmaceuticals; Tal Medical; VistaGen; Wyeth-Ayerst Laboratories 
Advisory Board/Consultant: Abbott Laboratories; Acadia; Affectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Avanir Pharmaceuticals; AXSOME Therapeutics; Bayer AG; Best Practice Project Management, Inc.; Biogen; BioMarin Pharmaceuticals, Inc.; BioXcel Therapeutics; Biovail Corporation; Boehringer Ingelheim; Boston Pharmaceuticals; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Cerecor; Clexio Biosciences; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; Forum Pharmaceuticals; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; Indivior; i3 Innovus/Ingenis; Intracellular; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; Marinus Pharmaceuticals; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Navitor Pharmaceuticals, Inc.; Nestle Health Sciences; Neuralstem, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG; Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Osmotica; Otsuka Pharmaceuticals; Pamlab, LLC.; Perception Neuroscience; Pfizer Inc.; PharmaStar; Pharmavite® LLC.; PharmoRx Therapeutics; Polaris Partners; Praxis Precision Medicines; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; PPD; PThera, LLC; Purdue Pharma; Puretech Ventures; PsychoGenics; Psylin Neurosciences, Inc.; RCT Logic, LLC ( formerly Clinical Trials Solutions, LLC); Relmada Therapeutics, Inc.; Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi-Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Shenox Pharmaceuticals, LLC; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Taisho Pharmaceuticals; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex; Teva Pharmaceuticals; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Usona Institute,Inc.; Vanda Pharmaceuticals, Inc.; Versant Venture Management, LLC; VistaGen
Speaking & Publishing: Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource,Corp.; Wyeth-Ayerst Laboratories
Equity Holdings: Compellis; PsyBrain, Inc., Sensorium Therapeutics  
Royalties, Patents: Patents for Sequential Parallel Comparison Design (SPCD), licensed by MGH to Pharmaceutical Product Development, LLC (PPD) (US_7840419, US_7647235, US_7983936, US_8145504, US_8145505); and patent application for a combination of Ketamine plus Scopolamine in Major Depressive Disorder (MDD), licensed by MGH to Biohaven. Patents for pharmacogenomics of Depression Treatment with Folate (US_9546401, US_9540691). 
Copyrights: For the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), Symptoms of Depression Questionnaire (SDQ), and SAFER; Lippincott, Williams & Wilkins; Wolkers Kluwer; World Scientific Publishing Co. Pte.Ltd.

Marlene P. Freeman, MD
Research Support: Investigator Initiated Trials /Research: JayMac, Sage; 
Dr. Freeman is an employee of Massachusetts General Hospital, and works with the MGH National Pregnancy Registry. MGH National Pregnancy Registry: Current Sponsors: Alkermes, Inc. (2016-Present); Aurobindo Pharma (2020-Present); AuroMedics Pharma LLC (2021-present); Johnson & Johnson/Janssen Pharmaceuticals, Inc (2019-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Sage Therapeutics (2019-Present); Sunovion Pharmaceuticals, Inc. (2011-Present); Supernus Pharmaceuticals (2021-Present); Teva Pharmaceutical Industries Ltd. (2018-Present).Past Sponsors: Forest/Actavis/Allergan (2016-2018, declined to sponsor: 2018-Present), AstraZeneca Pharmaceuticals (2009-2014, declined to sponsor: 2014-Present); Ortho-McNeil-Janssen Pharmaceuticals, Inc (2009-2014, declined to sponsor: 2015-Present); Pfizer, Inc. (2009-2011, declined to sponsor: 2012-Present).  As an employee of MGH, Dr. Freeman works with the MGH CTNI, which has had research funding from multiple pharmaceutical companies and NIMH.
Advisory Boards: Independent Data Safety and Monitoring Committees: Janssen (Johnson& Johnson), Novartis, Neurocrine; Advisory Boards: Eliem, Sage
Royalties: Scale Royalties- through MGH Scale, The Massachusetts General Hospital Female Reproductive Lifecycle and Hormones Questionnaire (Freeman et al. 2013) WebMD, Medscape, Pri-Med, Postpartum Support International

Oliver Freudenreich, MD, FACLP
Consultant: Alkermes, Neurocrine, Janssen 
Research Grant (PI): Avanir, Saladax, Janssen, Otsuka
Royalties: Wolters-Kluwer  
Royalties, Honoraria: UpToDate, Elsevier, MedScape, American Psychiatric Association

Michael E. Henry, MD
Salary (Spouse): Roche Pharmaceuticals

Franklin King, MD
Supervisor for study therapists: Cybin

David Mischoulon, MD, PhD
Research Support: Nordic Naturals, heckel medizintechnik GmbH
Salary Support: MGH clinical trials network and institute (CTNI)

Andrew A. Nierenberg, MD
Consultant, Honoraria, Royalties: Alkermes, Belvior, Clexio, Eisai, Ginger.io (Headspace Health), Guilford Publications, Janssen, Merck, Myraid

Roy H. Perlis, MD, MSc
Scientific Advisor: Genomind

Jerrold F. Rosenbaum, MD
Founder (Ownership Interest): Psy Therapeutics, Sensorium Therapeutics 

Susan Sprich, PhD (Psychologist Reviewer)
Royalties: Oxford University Press; Springer
Honorarium for associate editor of a journal: Association for Behavioral and Cognitive Therapies

Timothy E. Wilens, MD
Principal Investigator (Grant/Research Support): NIH (NIDA)
Consultant: Arbor Pharmaceuticals; Otsuka; KemPharm; Ironshore; Vallon
Intellectual Property (Licensing Agreement): Ironshore
Intellectual Property (Published book): Guilford Press
Intellectual Property (Co/edited textbook): Cambridge University Press
Clinical Consulting: Gavin Foundation; Bay Cove Human Services; US National Football League (ERM Associates); US Minor/Major League Baseball
Consultant (Shared IP): White Rhino/3D

Sabine Wilhelm, PhD
Royalties: Guilford Publications, New Harbinger Publications, Oxford University Press, Springer
Honorarium (Speaker): Tourrette Assocation of America, CDC and Prevention 
Research Grant, Scientific Advisory Board: Koa Health, Noom, INC, One-Mind PsyberGuid

Janet Wozniak, MD
Royalties (Spouse): UptoDate
Consultation Fees (Spouse): Emalex, Notrix, Dis Medcince, Avdadel, CVS
Research Support (Spouse): Merck, NeuroMetrix, American Regent,, NIDA,, RLS foundation and the Ellison Baszucki Research Fund
Research Support: PCORI
Author Royalties: Bantam Books

Lisa M. Zakhary, MD, PhD
Research Support: Promentis Pharmaceuticals, Inc.